BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Biotechnology

Healthcare
$1.81 -0.39%

-$0.03 today

Market cap
$144.85M
Beta
0.29
P/E (TTM)
-1.5
EPS (TTM)
-$4.95
52W Low $7.00High $14.87

Volume 0.58M

Average 0.37M

BBOT Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$398.67M, compared with -$244.58M a year earlier.

Context

  • Retained earnings amounted to 95.5% of total assets at the end of Q1 FY2026, down 67.8 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -63.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$398.67M-11.8% QoQ
Last fiscal yearDec 2025
-$356.57M-9451.4% YoY
Year agoMar 2025
-$244.58M-63.0% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-63.0%——
1 year-9451.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(356.57M) USD
Year-over-year change
-9451.4%

Retained Earnings vs competitors

How BBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -63.0% is the lowest of 10, against a peer median of -16.4%.
  • Retained earnings amounts to 95.5% of total assets for BBOT, versus a peer median of 169.4%.
BBOT Competitors
Retained Earnings for BBOT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SEPNSepterna, Inc.Sep 2026-$215.51M USD-37.7%—34.8%
BBOTBridgeBio Oncology Therapeutics Inc.Mar 2026-$398.67M USD-63.0%—95.5%
OCSOculis Holding AGMar 2026-CHF 412.13M CHF-29.3%—169.4%
NRIXNurix Therapeutics, Inc.Aug 2026-$630.13M USD+31.9%—52.7%
TNGXTango Therapeutics, Inc.Sep 2026-$772.4M USD-36.9%—74.7%
ANABAnaptysBio, Inc.Mar 2026-$825.44M USD-3.4%—250.4%
XNCRXencor, Inc.Jun 2026-$946.6M USD-20.9%—130.6%
URGNUroGen Pharma Ltd.Mar 2026-$983.29M USD-15.7%—387.6%
PHATPhathom Pharmaceuticals, Inc.Mar 2026-$1.51B USD-11.6%—496.4%
KODKodiak Sciences Inc.Sep 2026-$1.75B USD-16.4%—835.1%
Peer median (excluding BBOT) —-16.4%—169.4%

Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents0001.7M373.69M
Short-term Investments000051.77M
Net Receivables0000386K
Inventory00000
Other Current Assets0000(386K)
Total Current Assets0001.95M425.46M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments000192.45M132K
Tax Assets00000
Other Non-current Assets144.28K144.58K332.89K25.13K22.79M
Total Non-current Assets144.28K144.58K332.89K192.47M22.92M
Total Assets144.28K144.58K332.89K194.42M448.38M
Account Payables00001.37M
Short-term Debt36.96K43.11K70.1K00
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00005.75M
Total Current Liabilities162.64K166.46K396.46K187.52K35.04M
Long-term Debt00002.24M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0005.52M0
Total Non-current Liabilities0005.52M2.24M
Total Liabilities162.64K166.46K396.46K5.71M37.29M
Common Stock288288460192.45M8K
Retained Earnings(43.36K)(46.88K)(88.57K)(3.73M)(356.57M)
Accumulated OCI000016K
Other Stockholders Equity0172000
Minority Interest00000
Total Equity(18.36K)(21.88K)(63.57K)188.72M411.1M
Total Debt36.96K43.11K70.1K02.77M
Net Debt36.96K43.11K70.1K(1.7M)(370.92M)

BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Intrinsic Alpha fair value

Locked

Current Price

$1.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.